A decade of breast cancer clinical investigation: Results as reported in the program/proceedings of the American Society of Clinical Oncology

Journal of Clinical Oncology

Volumn 12, Issue 9, 1994, Pages 1789-1795

  Chlebowski, Rowan T ^a,b   Lillington, Linda M ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; LEVAMISOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHOTREXATE; PREDNISOLONE; PREDNISONE; TAMOXIFEN; VINCRISTINE;

ARTICLE; BLOOD; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; OVARIECTOMY; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0027974088     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1994.12.9.1789     Document Type: Article

References (33)

1. Editorial: Breast cancer: Have we lost our way? Lancet 341:343, 1993
2. Parkins T: The President's Special Commission on Breast Cancer to issue final report (News). J Natl Cancer Inst 85:1374, 1993
3. Henderson IC, Harris JR, Kinne DW, et al: Cancer of the breast, in DeVita VT, Hellman S, Rosenberg, SA (eds): Cancer - Principles and Practice of Oncology (ed 3) Philadelphia, PA, Lippincott, 1985, pp 1197-1258
4. Henderson IC, Harris JR: Principles in the management of metastatic disease, in Henderson IC, Hellman S, Harris JR, et al (eds): Breast Diseases. Philadelphia, PA, Lippincott, 1991, pp 547-559
5. Chlebowski RT: Treating the relapsed patient, in Henderson IC (ed): Adjuvant Therapy of Breast Cancer. Boston, MA, Kluwer Academic, 1992, pp 239-256
6. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
7. BMDP: Statistical Software Manual. Berkeley, CA, University of California, 1990
8. Bonadonna G, Valaguesa P, Rossi A, et al: CMF adjuvant program in operable breast cancer with positive axillary nodes: Tenyear experience. Proc Am Soc Clin Oncol 4:56, 1985 (abstr)
9. Rivkin SE, Glucksberg H, Foulkes M: Adjuvant chemotherapy for operable breast cancer with positive axillary nodes. Proc Am Soc Clin Oncol 3:125, 1984 (abstr)
10. Samal BA, Foulkes MA, McDonald B: Levamisole (L) probably shortens response and survival in CMFP-maintained advanced breast cancer patients. Proc Am Soc Clin Oncol 3:126, 1984 (abstr)
11. Carmo-Pereira J, Costa FO, Henrigues E, et al: Advanced breast carcinoma: A comparison of two dose levels of Adriamycin. Proc Am Soc Clin Oncol 5:56, 1986 (abstr)
12. Tannock IF, Boyd NF, Perrault DJ, et al: Randomized trial of two doses of CMF chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 6:50, 1987 (abstr)
13. Muss H, Paschold E, Black W, et al: Megestrol acetate vs tamoxifen in advanced breast cancer: A five year report. Proc Am Soc Clin Oncol 6:214, 1987 (abstr)
14. Blomqvist C, Elomaa I, Rissanen P, et al: The influence of treatment schedule on toxicity and efficacy of standard-dose FEC (cyclophosphamide-epiribicin-fluorouracil) in metastatic breast cancer - A randomized trial comparing weekly and four-weekly administration. Proc Am Soc Clin Oncol 11:74, 1992 (abstr)
15. T) for metastatic breast cancer (MBC): A phase III trial of the Piedmont Oncology Association (POA). Proc Am Soc Clin Oncol 8:22, 1989 (abstr)
16. Abraham JS, Cirrincione C, Aisner J, et al: A phase III dose-response trial of megestrol acetate (MA) in metastatic breast cancer. Proc Am Soc Clin Oncol 11:56, 1992 (abstr)
17. da Luz RJ, Moore JW, Tong D, et al: A re-appraisal of ovarian ablation for metastatic breast cancer. Proc Am Soc Clin Oncol 9:28, 1990 (abstr)
18. Muss H, Case LD, Fussell R, et al: Tamoxifen (T) versus high dose oral medroxyprogesterone acetate (MPA) as first line endocrine therapy (RX) for metastatic breast cancer (MBC): A randomized trial of the Piedmont Oncology Association. Proc Am Soc Clin Oncol 10:41, 1991 (abstr)
19. Pouillait P, Jouve M, Palangie T, et al: Metastatic breast cancer. Controlled trial studying the optimal timing of hormonotherapy combined with chemotherapy (preliminary report). Proc Am Soc Clin Oncol 3:129, 1984 (abstr)
20. Boccado F, Bruzzi P, Cappellini M, et al: Tamoxifen vs chemotherapy vs chemotherapy plus tamoxifen in stage II ER+ breast cancer patients. Proc Am Soc Clin Oncol 8:209, 1989 (abstr)
21. Fisher B, Redmond C, Poisson S, et al: Increased benefit from addition of adriamycin and cyclophosphamide (AC) to tamoxifen (T) for positive-node Tam-responsive postmenopausal breast cancer patients, results from NSABP B-16. Proc Am Soc Clin Oncol 9:72, 1990 (abstr)
22. Dombernowsky P, Zedeler K, Hansen M, et al: Randomized trial of adjuvant CMF + radiotherapy, CMF alone vs CMF plus tamoxifen in pre- and menopausal stage II breast cancer. Proc Am Soc Clin Oncol 11:44, 1992 (abstr)
23. Braversman AS: Chemotherapeutic failure: Resistance or insensitivity. Ann Intern Med 18:630-632, 1993
24. Freiman JA, Chalmers TC, Smith H, et al: The importance of beta, the type II error, and sample size in the design and interpretation of the randomized controlled trial. N Engl J Med 299:690-694, 1978
25. Chlebowski RT, Smalley RV, Weiner JM, et al: Combination versus sequential single agent chemotherapy in advanced breast cancer: Association with metastatic sites. Br J Cancer 63:1011-1042, 1989
26. Fraser SCA, Dobbs HJ, Ebbs SR, et al: Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of Life. Br J Cancer 67:402-406, 1993
27. Coates AS, Gelski V, Signori D, et al: Prognostic value of quality of life scores during chemotherapy for advanced breast cancer. J Clin Oncol 10:1833-1838, 1992
28. Houston SJ, Richards MA, Bentley AE, et al: The influence of adjuvant chemotherapy on outcome after relapse in patients with breast cancer. Proc Am Soc Clin Oncol 11:108, 1992 (abstr)
29. Louvet C, de Gramont A, Demuynck B, et al: Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. Eur J Cancer 29:1835-1838, 1993
30. Goldhirsch A, Gelber RD, Price KN, et al: Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 343:377-381, 1994
31. Smith TJ, Buonauito DA, Hillner BE, et al: The learning curve for cost of autologous bone marrow transplantation (ABMT) for breast cancer. Proc Am Soc Clin Oncol 12:54, 1993 (abstr)
32. Peters WP, Rogers MC: Variations in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer. N Engl J Med 330:473-477, 1994
33. Frei E III, Freireich EJ: The clinical cancer researcher - Still an embattled species. J Clin Oncol 11:1639-1651, 1993